Risperidone 2 MG Disintegrating Oral Tablet [Risperdal] — RxCUI 806299
RxNorm drug concept · Semantic branded drug
RxCUI 806299
Semantic branded drug · SBD
Retired or remapped concept 11 FDA products
10 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI806299
Official nameRisperidone 2 MG Disintegrating Oral Tablet [Risperdal]
Concept typeSemantic branded drug (SBD)
RxNorm statusRetired or remapped concept
FDA products mapped11
Package NDCs mapped10
Reported Medicaid activity (SDUD)2,806 prescriptions · 13 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Risperidone: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- It treats schizophrenia and bipolar I disorder. The oral forms also treat irritability linked to autistic disorder in children and adolescents. Which condition applies depends on t...
- Oral risperidone can be taken with or without food, because food doesn't change how well it's absorbed. Take it as your prescriber directed. The injections are given by a healthcar...
- Common ones include sleepiness, dizziness, restlessness, tremor, stiffness, nausea, constipation, dry mouth and weight gain. Tell your prescriber if they bother you. Don't stop on...
- Call for fever with muscle stiffness or confusion, uncontrolled movements, stroke symptoms, seizures, signs of high blood sugar like extreme thirst, or a painful erection that won'...
🕸️ Concept Web
No related-concept groups were available for this RxCUI in the loaded RxNorm data. That does not prove that no related concepts exist.
📦 FDA Products & Package NDCs
11 products · 10 package NDCs
10 package NDCs map to RxCUI 806299 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 50458-0300-01 | 10 BLISTER PACK in 1 BOX, UNIT-DOSE (50458-300-01) / 10 TAB... | RISPERDAL | Janssen Pharmaceuticals, Inc. | 1993-12-29 |
| 50458-0300-06 | 60 TABLET in 1 BOTTLE (50458-300-06) | RISPERDAL | Janssen Pharmaceuticals, Inc. | 1993-12-29 |
| 50458-0302-01 | 10 BLISTER PACK in 1 BOX, UNIT-DOSE (50458-302-01) / 10 TAB... | RISPERDAL | Janssen Pharmaceuticals, Inc. | 1993-12-29 |
| 50458-0302-06 | 60 TABLET in 1 BOTTLE (50458-302-06) | RISPERDAL | Janssen Pharmaceuticals, Inc. | 1993-12-29 |
| 50458-0305-03 | 30 mL in 1 BOTTLE (50458-305-03) | RISPERDAL | Janssen Pharmaceuticals, Inc. | 1996-06-10 |
| 50458-0320-01 | 10 BLISTER PACK in 1 BOX, UNIT-DOSE (50458-320-01) / 10 TAB... | RISPERDAL | Janssen Pharmaceuticals, Inc. | 1993-12-29 |
| 50458-0320-06 | 60 TABLET in 1 BOTTLE (50458-320-06) | RISPERDAL | Janssen Pharmaceuticals, Inc. | 1993-12-29 |
| 50458-0330-06 | 60 TABLET in 1 BOTTLE (50458-330-06) | RISPERDAL | Janssen Pharmaceuticals, Inc. | 1993-12-29 |
| 50458-0350-01 | 10 BLISTER PACK in 1 BOX, UNIT-DOSE (50458-350-01) / 10 TAB... | RISPERDAL | Janssen Pharmaceuticals, Inc. | 1993-12-29 |
| 50458-0350-06 | 60 TABLET in 1 BOTTLE (50458-350-06) | RISPERDAL | Janssen Pharmaceuticals, Inc. | 1993-12-29 |
Observed labelers:
Janssen Pharmaceuticals, Inc. (10)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.